Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers.

Kölzer, Viktor; Huber, Bettina; Mele, Valentina; Iezzi, Giandomenica; Trippel, Mafalda; Karamitopoulou, Evanthia; Zlobec, Inti; Lugli, Alessandro (2015). Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers. Human pathology, 46(11), pp. 1573-1581. Elsevier 10.1016/j.humpath.2015.07.010

[img] Text
1-s2.0-S0046817715002580-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

Expression of the hyaluronan-mediated motility receptor (RHAMM, CD168) predicts adverse clinicopathological features and decreased survival for colorectal cancer (CRC) patients. Using full tissue sections, we investigated the expression of RHAMM in tumor budding cells of 103 primary CRCs to characterize the biological processes driving single-cell invasion and early metastatic dissemination. RHAMM expression in tumor buds was analyzed with clinicopathological data, molecular features and survival. Tumor budding cells at the invasive front of CRC expressed RHAMM in 68% of cases. Detection of RHAMM-positive tumor budding cells was significantly associated with poor survival outcome (P = .0312), independent of TNM stage and adjuvant therapy in multivariate analysis (P = .0201). RHAMM-positive tumor buds were associated with frequent lymphatic invasion (P = .0007), higher tumor grade (P = .0296), and nodal metastasis (P = .0364). Importantly, the prognostic impact of RHAMM expression in tumor buds was maintained independently of the number of tumor buds found in an individual case (P = .0246). No impact of KRAS/BRAF mutation, mismatch repair deficiency and CpG island methylation was observed. RHAMM expression identifies an aggressive subpopulation of tumor budding cells and is an independent adverse prognostic factor for CRC patients. These data support ongoing efforts to develop RHAMM as a target for precision therapy.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute of Pathology > Clinical Pathology
04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Kölzer, Viktor; Trippel, Mafalda; Karamitopoulou, Evanthia; Zlobec, Inti and Lugli, Alessandro

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

0046-8177

Publisher:

Elsevier

Language:

English

Submitter:

Doris Haefelin

Date Deposited:

29 Oct 2015 12:56

Last Modified:

04 Nov 2015 09:01

Publisher DOI:

10.1016/j.humpath.2015.07.010

PubMed ID:

26351067

Uncontrolled Keywords:

CD168; Colorectal cancer; Hyaluronan acid–mediated motility receptor; Prognostic factor; RHAMM; Tumor budding

BORIS DOI:

10.7892/boris.72357

URI:

https://boris.unibe.ch/id/eprint/72357

Actions (login required)

Edit item Edit item
Provide Feedback